Recent work has demonstrated that N-MYC amplified gliomas, exerting dramatically increased dependence on glycolysis, may be particularly susceptible to NAMPT inhibition as an anti-metabolic therapy (35, 36). The gene discussed is NAMPT; the disease is glioma.